Growth leadership Recent C-suite changes signal a transition in leadership with Andrea Valente stepping up to CEO and James Thatcher joining as Chief Commercial Officer. This presents an opportunity to engage on strategic partnerships, enterprise deals, and refreshed commercial roadmap.

Expansion momentum Strategic acquisition of ClinOne in 2024 and ongoing international cloud hosting across US, Europe, and China indicates a broader platform footprint and capability expansion. Sell opportunities around integrated patient-site journeys, expanded site tools, and cross-sell of trial management capabilities.

Clinical trial focus uMotif’s eCOA platform emphasized for faster, higher-quality trials with strong patient retention and consent management features. Target CROs, biotech, and pharma seeking improved patient engagement and regulatory compliance (GCP 21 CFR Part 11 and GDPR) across multiple indications.

Strategic partnerships Existing collaborations with MoCA Cognition, Oxford Bi Network, and Cmocro reflect a pattern of ecosystem partnerships to enhance CNS research and patient-facing solutions. Leverage these ties to pursue joint go-to-market and co-development opportunities.

Financial signals Reported revenue in the range of tens of millions places uMotif as a growing mid-market player with scalable needs. Priorities likely include investment in commercial expansion, platform integrations, and international compliance capabilities to support growth.